ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "psoriatic arthritis and quality of life"

  • Abstract Number: 649 • 2015 ACR/ARHP Annual Meeting

    Measures of Health-Related Quality of Life in Psoriatic Arthritis: Are They Sensitive to Both Joint and Skin Aspects?

    Mwidimi Ndosi1, Ming-Anne Hsu2, J. Cappelleri3, Amit Chhabra4, Heather Jones5 and Philip S. Helliwell6, 1School of Healthcare, University of Leeds, Leeds, United Kingdom, 2445 Eastern Point Road, Pfizer Inc, Groton, CT, 3Statistics, Pfizer Inc, New London, CT, 4Pfizer Inc, Collegeville, PA, 5Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, 6Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Psoriatic Arthritis Quality of Life (PsAQol), Ankylosing Spondylitis Quality of Life (ASQoL), and Dermatology Life Quality Index (DLQI) are tools that assess different aspects of health-related…
  • Abstract Number: 654 • 2015 ACR/ARHP Annual Meeting

    Associations Between Skin Outcomes By Body Area Affected and Health-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol

    Alice B. Gottlieb1, Bengt Hoepken2, Luke Peterson3 and Peter C. Taylor4, 1Dermatology, Tufts Medical Center, Boston, MA, 2UCB Pharma, Monheim, Germany, 3UCB Pharma, Raleigh, NC, 4Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom

    Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) report poorer health-related quality of life (HRQoL) compared to the general population. As with psoriasis (PSO), it is…
  • Abstract Number: 657 • 2015 ACR/ARHP Annual Meeting

    Routine Assessment of Patient Index Data 3 Score (RAPID3) and Psoriasis Quality of Life (PQoL-12) Assess Different Domains in Psoriasis (PsO) and Psoriatic Arthritis (PsA) Patients

    Kiana Vakil-Gilani1, Alexis Dinno2, Neha Garg3 and Atul A. Deodhar4, 1Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, 2School of Community Health, Portland State University, Portland, OR, 3Rheumatology, Oregon Health and Science University, Portland, OR, 4Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

    Background/Purpose: PQoL-12 is a validated composite tool (range: 0–120) assessing patients' quality of life in PsO and PsA. RAPID3 is another validated composite index (range:…
  • Abstract Number: 658 • 2015 ACR/ARHP Annual Meeting

    Health Related Quality of Life in Psoriatic Arthritis from the Perspective of People Living with the Condition

    Ana-Maria Orbai1,2, Suzanne Grieb3, Clifton Bingham4, Michelle Jones4, Grazyna Purwin5 and Katherine Clegg-Smith6, 1Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Rheumatology, Johns Hopkins University, Baltimore, MD, 3Johns Hopkins Bayview Medical Center, Center for Child and Community Health Research, Baltimore, MD, 4Johns Hopkins University, Baltimore, MD, 5Johns Hopkins Arthritis Center, Baltimore, MD, 6Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

    Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory disease with variable phenotype affecting skin, joints, ligaments/tendons, nails, and the spine. Heterogeneity of clinical manifestations complicates…
  • Abstract Number: 1548 • 2014 ACR/ARHP Annual Meeting

    Treatment Effect of Ustekinumab on Fatigue in Patients with Psoriatic Arthritis: Results from a Phase 3 Clinical Trial

    Christopher T. Ritchlin1, Proton Rahman2, Lluís Puig Sanz3, Alice B. Gottlieb4, Arthur Kavanaugh5, Iain B. McInnes6, Shu Li7, Yuhua Wang7, Rita Ganguly8, Alan M. Mendelsohn9 and Chenglong Han8, 1Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 3Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Tufts Medical Center, Boston, MA, 5University of California San Diego, La Jolla, CA, 6Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 7Janssen Research & Development, LLC., Spring House, PA, 8Janssen Global Services, LLC., Malvern, PA, 9Immunology, Janssen Research & Development, LLC., Spring House, PA

    Background/Purpose: To assess the treatment effect of ustekinumab on fatigue using data from PSUMMIT 2. Methods: Adult patients with active psoriatic arthritis (PsA) despite DMARD…
  • Abstract Number: 322 • 2013 ACR/ARHP Annual Meeting

    Ustekinumab Improves Physical Function, Quality Of Life, and Work Productivity Of Patients With Active Psoriatic Arthritis Who Were Methotrexate-naïve Or Previously Treated With Methotrexate Or Anti-Tumor Necrosis Factor Agent:Data From 2 Phase 3, Randomized, Placebo-Controlled Trials

    Proton Rahman1, Lluis Puig2, Alice B. Gottlieb3, Arthur Kavanaugh4, Iain B. McInnes5, Christopher T. Ritchlin6, Shu Li7, Yuhua Wang7, Ning Zhao8, Rita Ganguly8, Michael Song7, Alan M. Mendelsohn9 and Chenglong Han8, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Universitat Autònoma de Barcelona, Barcelona, Spain, 3Tufts Medical Center, Boston, MA, 4University of California, San Diego, La Jolla, CA, 5Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 6Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 7Janssen Research & Development, LLC., Spring House, PA, 8Janssen Global Services, LLC., Malvern, PA, 9Immunology, Janssen Research & Development, LLC., Spring House, PA

    Background/Purpose: To examine the impact of ustekinumab (UST) treatment on patient reported outcomes in patients with active psoriatic arthritis (PsA) using week 24 data from…
  • Abstract Number: 329 • 2013 ACR/ARHP Annual Meeting

    Health-Related Quality Of Life In Early Psoriatic Arthritis In Comparison With Early Rheumatoid Arthritis. A 5-Year Follow-Up Report From The Swedish Early Psoriatic Arthritis Registry and The Swedish Early Intervention In RA Registry

    Lars Törnqvist1, Tomas Husmark2, Ulla R. C. Lindqvist3, Gerd-Marie Alenius4, Per Larsson5, Annika Teleman6, Mats Geijer7, Lars Erik Kristensen8, Ingrid Thyberg9 and Elke Theander10, 1Department of Rheumatology, Skåne University Hospital Malmö, Lund University, Sweden, Malmö, Sweden, 2Department of Rheumatology, Falu Hospital, Falun, Sweden, 3Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden, 4Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, 5Dept of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, 6Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, 7Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden, 8Rheumatology, Skåen University Hospital, Lund University, Lund, Sweden, 9Rheumatology, Linköping University Hospital, Linkoping, Sweden, 10Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: Studies on early psoriatic arthritis (ePsA) are still rare and data on health related quality of life (HRQoL) in ePsA are lacking completely.  To…
  • Abstract Number: 1557 • 2013 ACR/ARHP Annual Meeting

    Assessing The Real Life Impact Of Psoriatic Arthritis On Disability, Quality Of Life, and Provider Satisfaction

    M. Elaine Husni1, Daniel Duch2 and Neil J. Korman3, 1Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, 2Curatio CME Institute, Exton, PA, 3Case Western Reserve Univ (Uni, University Hospitals Dermatolo, Cleveland, OH

    Background/Purpose: Despite the availability of more targeted therapies for psoriatic arthritis (PsA), an assessment of the impact these have had on patient well-being has not recently…
  • Abstract Number: 995 • 2013 ACR/ARHP Annual Meeting

    Quality Of Life, Productivity Impairment, Disease Severity and Health Care Costs In Relation To Functional Impairment In Psoriatic Arthritis Patients In The Czech Republic

    Jiri Stolfa1,2, Liliana Sedova1,2, David Suchy3, Jiri Klimes4, Milan Vocelka4 and Tomas Dolezal4, 1Institute of Rheumatology, Prague, Czech Republic, 2Clinic of Rheumatology, Charles University Prague, Prague, Czech Republic, 3Department of Clinical Pharmacology, Rheumatology, University hospital Plzen, Plzen, Czech Republic, 4Institute of Health Economics and Technology Assessment, Charles University, Prague, Czech Republic

    Background/Purpose: Our aim was to describe the QoL, productivity impairment, clinical indicators and health care costs in relationship to functional status described by Health assessment…
  • Abstract Number: 1828 • 2012 ACR/ARHP Annual Meeting

    Smoking Is Associated with Worse and More Widespread Pain, Worse Fatigue, General Health and Quality of Life in a Swedish Population Based Cohort of Patients with Psoriatic Arthritis

    Ann B. I. Bremander1, Lennart TH Jacobsson2, Stefan Bergman3, Emma Haglund4 and Ingemar F. Petersson5, 1Department of Exercise Physiology, Biomechanics and Health, Halmstad University School of Business and Engineering, Halmstad, Sweden, 2Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 3Spenshult Research and Development Center, Halmstad, Sweden, 4Research and Development Centre, Spenshult Hospital for Rheumatic Diseases, Halmstad, Sweden, 5Lund University, Lund, Sweden

    Background/Purpose: Smoking has been found to be associated with an increased risk of developing psoriatic arthritis (PsA). The purpose of this study was analyse possible…
  • Abstract Number: 540 • 2012 ACR/ARHP Annual Meeting

    The Predictors of Reduced Work Productivity in Patients with Psoriatic Arthritis

    Anjali Papneja1, Matthew Kennedy2, Arane Thavaneswaran3, Daniel Pereira4, Vinod Chandran5 and Dafna D. Gladman6, 1Rheumatology, University of Toronto, Toronto, ON, Canada, 2Medicine, University of Toronto, TOronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 5University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 6Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA) is a unique inflammatory musculoskeletal disorder associated with psoriasis. Related to its detrimental impact on health and quality of life, PsA…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology